

Twitter Thread by [Alhaspot Capital](#)



[Alhaspot Capital](#)

[@alhaspotcap](#)



Divi's Lab Analysis■■■

A detailed thread ■■■■

#investing #StocksToBuy



(1/17)

About:

DLL was incorporated in 1990 by Dr Murli K Divi. DLL is engaged in manufacturing of generic APIs, Nutraceutical, Custom Synthesis of APIs & Intermediates for innovator companies

Divi's Lab is the leading manufacturer of APIs, supplying to over 95 countries.

(2/17)

Global Pharma Industry:

The pharma industry will be closely monitored by govt in all countries in times to come.

The industry is expected to grow at 3–6% CAGR through 2025, reaching about \$1.6 trillion in total market size in 2025.

(3/17)

Indian pharma industry:

India ranks 3rd worldwide for pharmaceutical production by volume & 14th by value.

The Indian active ingredients industry has progressed from being an industry manufacturing simple molecules to manufacturing high value and complex APIs.

(4/17)

The Man behind Divis Lab!

Dr. Murli K. Divi is a postgraduate in Pharmaceutical Chemistry from College of Pharmacy, Manipal

He has over 30 years of experience in this field

He has previously worked with Trinity Chemical Corporation, Schuylkill Chemical & Fike Chemicals

(5/17)

Catering to Diversified Geography:

Here is the Revenue breakup by region:

1. India : 12%

2. Asia : 12.4%

3. Europe : 47.4%

4. North America : 23.7%

5. ROW : 4.5%

(6/17)

Best in class financial ratios:

1. Return on Net Worth : 21.08%
2. ROCE : 34.69%
3. Basic EPS : 73.63
4. Debt to Equity : 0.00
5. OPM % : 42%
6. NPM % : 28.5%
7. Sales growth : 25.2%
8. ROE : 23.9%

(7/17)

Business segments:

Divis lab has 2 product categories

1. Generic APIs & Nutraceuticals
2. Custom Synthesis of APIs, intermediaries & specialty ingredients for innovator pharma Giants

Top 5 products account for 49% of revenue

Top 5 customers account for 34% of revenue

(8/17)

Shareholding Pattern:

1. Promoters : 51.97%
2. Mutual funds: 14.67%
3. FIIs : 19.08%
4. Indian Public : 8.57%
5. Others : 5.71%

Shareholding Profile:

1. NSDL : 97.10%
2. CDSL: 2.83%
3. Physical: 0.07%

(9/17)

Key Growth Drivers:

1. Healthy growth prospects of the industry:

Pharma exports are expected to grow by 8%-10% on a you basis & the increase in exports will be backed by higher exports to USA, pharmemerging nations and developed nations

(10/17)

2. Custom Synthesis:

Divi's Custom synthesis division is on strong footing and company is engaged with 6 out of 10 pharma companies across the US, EU and Japan.

High entry barrier in this segment offers superior growth & margin compared to pharma generic business.

(11/17)

3. Fruits of capex expansion:

Divis lab was one of the first to focus on backward integration. This has helped them to solidify supply chain management & cost reduction due to focus on improving technology

(12/17)

4. China +1 in API:

India used to import ~70% of Pharma API from China. Then GOI announced a package of ■10,000 crore stimulus package to boost up the domestic pharma API industry

So, it is a huge opportunity for Divis as ~50% of its revenue comes from generic API.

(13/17)

Recent developments:

1. The company is operating at 80-85% of production capacity.

2. Targeting molecules whose patent expires in 2023–25, to tune of \$20bn patent getting expired.

3. Divis is anticipating ■100cr capex to be capitalized in Q4FY22.

(14/17)

Key Risk:

1. High exposure to forex fluctuation risk:

DLL is exposed to forex risk as major revenue of the company is derived from exports.

Divi's imports around 50% of the raw material consumption which provides natural hedge to the tune of around 25%.

(15/17)

2. Exposure to regulatory risk:

The pharma industry is highly regulated & requires various licenses & permissions for business

Each authority has its own requirement & they could refuse to grant approval, even when a product has already been approved in another country

(16/17)

Conclusion:

Divis Lab has a very strong margin levels and forward looking management. They have established track record in CRAMS segment with reputed clientele & strong R&D capabilities.

However, product concentration risk & forex risk should be analysed carefully.

(17/17)

What are your thoughts about Divi's Labs fundamentals?

[@caniravkaria](#) [@kuttrapali26](#) [@stockifi_Invest](#) [@MadhusudanKela](#) [@VRtrendfollower](#)